300147 ST香雪制药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,145,913-25.28%1,858,6622,299,2882,187,0702,970,576
减:营业总成本1,413,592-18.38%2,266,7422,452,4742,575,6693,167,436
    其中:营业成本784,032-25.80%1,405,8071,509,5211,643,1732,189,989
               财务费用203,51012.59%231,011241,471212,510202,750
               资产减值损失(25,693)1,620.76%(380,109)(163,342)(138,578)(482,077)
公允价值变动收益630-574.45%6362,728(12)15,641
投资收益452-96.93%(6,000)(50,640)47,32933,589
    其中:对联营企业和合营企业的投资收益(511)20.22%(1,343)(52,159)903(19,543)
营业利润(277,173)77.35%(784,525)(332,716)(464,142)(575,277)
利润总额(335,222)78.46%(842,071)(388,951)(511,864)(622,344)
减:所得税费用3,866-57.29%19,15412,795(7,215)24,458
净利润(339,088)72.22%(861,224)(401,746)(504,648)(646,801)
减:非控股权益22,8149.11%(2,664)(12,782)25,41029,772
股东净利润(361,902)66.16%(858,560)(388,964)(530,058)(676,573)

市场价值指针
每股收益 (元) *-0.55066.67%-1.300-0.590-0.800-1.020
每股派息 (元) *------------
每股净资产 (元) *1.047-59.42%1.5952.9113.6374.454
审计意见 #--标准的无保留意见保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容